Q1 2023 Evonik

Q1 adj. EBITDA of only €409 m due to low volumes and despite positive pricing in Specialties;
PA12 ramp-up driving Smart Materials, slow start in Specialty Additives, price pressure in Animal Nutrition and C4.

Positive pricing
in Specialties
despite low volumes.

 

Free Trial

Step 1 of 2

This field is for validation purposes and should be left unchanged.
Name(Required)

By pressing “Send” you agree to the Privacy Policy of this site

No Credit Card needed, after filling up the form you will receive your Free-Trial login information in 24 to 48 hours by e-mail.

ImprintPrivacy Policy

All Rights Reserved © aicorite.com